RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (European Union), PRIME (European Union), Breakthrough Therapy (China)

Structure/Sequence

Boost your research with our RNA technology data.

view full example data

Sequence Code 286629921

Source: *****

Sequence Code 1191632800

Source: *****

Clinical Trials associated with Elebsiran

NCT07142811

/ Active, not recruitingPhase 2

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection

Start Date05 Aug 2025

Sponsor / Collaborator

Vir Biotechnology, Inc.

NCT07128550

/ Active, not recruitingPhase 3

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

Start Date30 Jul 2025

Sponsor / Collaborator

Vir Biotechnology, Inc.

NCT06903338

/ Active, not recruitingPhase 3

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.

Start Date12 Mar 2025

Sponsor / Collaborator

Vir Biotechnology, Inc.

100 Clinical Results associated with Elebsiran

100 Translational Medicine associated with Elebsiran

100 Patents (Medical) associated with Elebsiran

Literatures (Medical) associated with Elebsiran

01 Apr 2026·JHEP Reports

Elebsiran and pegylated-IFNα: Progress toward a functional cure for chronic hepatitis B

Article

Author: Battistella, Sara ; Forns, Xavier ; Protzer, Ulrike

04 Mar 2026·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models

Article

Author: Bakardjiev, Anna ; Purcell, Lisa A ; Noack, Julia ; LeBlanc, Sarah ; Gall, Jonathan ; Zhou, Jiayi ; Corti, Davide ; Jadhav, Vasant ; Liebow, Abigail ; Anglero-Rodriguez, Yesseinia ; Hebner, Christy M ; Lempp, Florian A

ABSTRACT:

RNA interference (RNAi) therapeutics targeting hepatitis B virus (HBV) RNAs and monoclonal antibodies (mAbs) targeting HBV surface antigen (HBsAg) represent potential strategies for enabling functional cure in chronic HBV patients. Tobevibart (VIR-3434) is an investigational, Fc-engineered human mAb that targets HBsAg with pan-genotypic neutralizing activity. Elebsiran (VIR-2218) is an investigational small interfering RNA targeting a conserved region of the HBV genome. The in vitro antiviral activity of elebsiran was assessed in HBV-infected primary human hepatocytes and hepatoma cells and showed potent inhibition of viral markers HBeAg (EC 50 of 2.5 nM and 53.7 pM, respectively) and HBsAg (EC 50 of 1.4 nM and 66.5 pM, respectively). Tobevibart and elebsiran activity in vivo was determined using two well-established HBV mouse models: AAV-HBV transduced C57BL/6 mice and human liver-chimeric mice. Mice were treated with a monotherapy or a combination of muHBC34 (the murinized parental mAb of tobevibart) and elebsiran at different doses. In both models, the mouse surrogate of tobevibart or elebsiran monotherapy was effective in reducing blood HBsAg levels. Combined treatment improved suppression of HBsAg (maximum mean reductions of 2.81 log in the AAV-HBV model and 2.51 log in human liver-chimeric mice) and HBV DNA over monotherapy. Tobevibart and elebsiran have been tested in clinical trials for the treatment of chronic hepatitis B and chronic hepatitis Delta.

01 Mar 2026·JOURNAL OF HEPATOLOGY

Tobevibart and elebsiran for the treatment of chronic hepatitis delta

Article

Author: Sandmann, Lisa

151

News (Medical) associated with Elebsiran

03 Jul 2026

·www.prnewswire.com

Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ENSURE Cohorts 2 and 3, informing selection of combination regimen going forward As previously disclosed, advancement of ENRICH into Phase 3 remains subject to the outcome of arbitration with Vir Biotechnology regarding the elebsiran manufacturing technology transfer DURHAM, N.C. and BEIJING, July 2, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigating sequential versus concurrent combination regimens of BRII-179 with elebsiran and PEG-IFNα for chronic hepatitis B virus (HBV) infection. The ENRICH and ENHANCE studies are two Phase 2b studies designed to further define the role of BRII-179 in chronic HBV treatment and to select the optimal combination regimen for future development. The ENRICH study evaluates BRII-179 as a priming therapy administered prior to elebsiran and PEG-IFNα treatment. The ENHANCE study evaluates a concurrent triple combination regimen of BRII-179, elebsiran, and PEG-IFNα to enhance the functional cure rates. At EOT, the ENRICH study evaluating pre-treatment with BRII-179 followed by elebsiran and PEG-IFNα demonstrated hepatitis B surface antigen (HBsAg) loss rates of 42.9% (42/98) and 40.0% (20/50) across two different BRII-179 dosing schedules, being 5 doses administered once every 3 weeks versus 7 doses administered once every 2 weeks, respectively. These results were consistent with the HBsAg loss rate observed in ENSURE Cohort 4, 41.9% (13/31) in patients with prior BRII-179 treatment, supporting the immune priming role of BRII-179. The Company had engaged with the Center for Drug Evaluation of the National Medical Products Administration of China and reached preliminary alignment regarding a potential registrational study. At EOT, the ENHANCE (Part A-1) study evaluating a concurrent triple combination did not demonstrate improved HBsAg loss rates compared with ENSURE Cohorts 2 and 3, 29.7% (11/37), with an observed rate of 25.5% (25/98). However, higher HBsAg loss rates were observed compared with the PEG-IFNα control arm, 10.2% (5/49). Subgroup analyses from the ENRICH study suggest potential differentiation in subjects with higher baseline HBsAg levels (1000-3000 IU/mL), consistent with prior findings from ENSURE Cohort 4, indicating that BRII-179 may induce beneficial immune responses regardless of baseline HBsAg levels in this difficult-to-treat population. The ENHANCE study, Part A-2, also evaluated a sequential approach designed to potentially shorten PEG-IFNα therapy by administering BRII-179 plus elebsiran during the first 24 weeks followed by 24 weeks of elebsiran and PEG-IFNα. At EOT, this combination regimen achieved an HBsAg loss rate of 22.5% (18/80), suggesting full course of PEG-IFNα therapy is needed for optimal curative outcome. HBsAg loss is an important endpoint when evaluating functional cure regimens, but requires confirmation during off-treatment follow-up to assess rebound and durability of functional cure. No new safety concerns were identified in either study. The Company plans to present detailed data, including additional efficacy, safety, subgroup analyses and follow-up results, at a scientific conference in the second half of 2026. "These initial EOT data provide important insights into the relative performance of the ENRICH and ENHANCE study designs," said Dr. David Margolis, M.D., the Chief Medical Officer of the Company. "While longer-term follow-up is needed to assess durability of the HBsAg loss, the data observed to date, together with EOT and post-EOT findings from multiple prior studies, are very consistent, suggesting that the ENRICH study design is preferred for a registrational study. We look forward to sharing the more complete dataset later this year." As previously disclosed, in light of the ongoing arbitration between the Company and Vir Biotechnology, Inc., and the unknown nature and timing of the outcome of the Arbitration or any mutual resolution of the claims, the Company considers the future of the elebsiran program to be uncertain. In particular, the Company cannot invest in a Phase 3 clinical study of any elebsiran-containing combination therapy for HBV unless and until the claims in the Arbitration are satisfactorily resolved. The Company will continue to evaluate such developments and assess their impact on the continued viability of the elebsiran program, and update its shareholders and the public as and when appropriate in accordance with relevant requirements. For more information about Brii Bio's HBV programs visit . About Hepatitis B Hepatitis B virus (HBV) infection is one of the world's most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.1 HBV is of exceptional concern in China, where 87 million people are chronically infected.[2] About BRII-179 BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the "CDE") of China's National Medical Products Administration (the "NMPA") granted BRII-179 Breakthrough Therapy Designation. About Elebsiran Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade HBV RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020. In May 2024, the CDE of China's NMPA granted elebsiran Breakthrough Therapy Designation. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to improve patients' health by addressing high unmet medical needs with limited treatment options. The Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in both China and the United States. For more information, visit . SOURCE Brii Biosciences Limited 21% more press release views with Request a Demo

Clinical ResultPhase 2Breakthrough Therapy

27 May 2026

·www.prnewswire.com

Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV

- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII‑179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit - Data from an ENSURE translational study demonstrated that BRII‑179-induced epitope-mismatched CD4+ T cells and HBs‑specific B cell maturation were associated with enhanced HBsAg loss following curative treatment, offering additional insights into its potential mechanisms DURHAM, N.C. and BEIJING, May 27, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-study (EOS) data from Cohorts 1-4 of its Phase 2 ENSURE study at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain. The ENSURE study (NCT05970289) is a multicenter, open-label Phase 2 study in the Asia-Pacific region. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to the combination treatment with PEG-IFNα in participants with chronic hepatitis B virus (HBV) infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Cohort 4 evaluated a novel sequential combination treatment strategy for HBV utilizing Brii Bio's therapeutic vaccine, BRII-179, to prime and enrich participants with a goal of improving responsiveness to curative therapies. Participants previously treated with 9 doses of BRII-179 and elebsiran in the prior Phase 2 study BRII-179-835-001 (NCT04749368) were enrolled and received 48 weeks of combination treatment with elebsiran and PEG-IFNα. These participants were categorized as BRII-179 anti-HBs responders or non-responders based on whether their peak hepatitis B surface antibody (anti-HBs) titers exceeded 10 IU/L during the prior study. All participants were maintained on nucleos(t)ide analogues (NAs) for an additional 24 weeks upon completion of PEG-IFNα + elebsiran treatment. Functional cure rates at the end of ENSURE study, defined as sustained HBsAg loss with undetectable HBV DNA for at least 24 weeks after stopping all treatment, including NAs, are presented. Final results demonstrated that the HBsAg loss benefit observed in the elebsiran and PEG-IFNα combination cohorts translated into a higher functional cure rate compared to the PEG-IFNα alone cohort. BRII-179-experienced participants achieved higher functional cure rates, particularly among anti-HBs responders, suggesting that BRII-179 may play an important role in achieving durable immunological control of HBV. Brii Bio is conducting two additional Phase 2b trials to further define the role of BRII-179 in the treatment of chronic HBV infection and to optimize combination regimens for pivotal studies. The ENRICH study is evaluating the role of BRII-179 in priming HBV-specific immunity and identifying immuno-responsive patients with a higher likelihood of achieving functional cure. The ENHANCE study consists of two parts: one evaluating concurrent triple combination therapy with BRII-179, elebsiran and PEG-IFNα for 48 weeks, and another evaluating a sequential regimen of BRII-179 and elebsiran for 24 weeks followed by triple combination therapy for 24 weeks. End-of-treatment (EOT) data from both studies are expected to be presented in 2026. "We are encouraged by the consistency of the findings observed throughout the ENSURE study and believe these final results highlight the potential of BRII-179 and elebsiran in improving functional cure outcomes," said David Margolis, M.D., Chief Medical Officer of Brii Bio. "Together with upcoming data from our ongoing studies, these results provide important insights to guide the future development of our HBV functional cure program." Details of the late-breaker poster presentation are as follows: Title: Functional cure rate in chronic hepatitis B virus infected participants receiving elebsiran and pegylated interferon alfa: final results from the phase 2 ENSURE study Session/Presentation Type: Late-breaker posters Session Time: May 27, 08:30 - May 30, 16:00 (UTC+1) Abstract Number/Identifier: LB26-5012/ LBP-040 Presenter: Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China At Week 72 (24 weeks post EOT), 19 of 20 participants who achieved HBsAg loss met NA discontinuation criteria and stopped NA for the additional 24-week follow-up; One participant remained HBeAg positive. In Cohorts 1-3, functional cure was achieved in 2/19 (10.5%) and 3/18 (16.7%) participants from the elebsiran 200 mg or 100 mg + PEG-IFNα cohorts, respectively, compared with 1/18 (5.6%) in the PEG-IFNα cohort. In Cohort 4, functional cure was achieved in 8/31 (25.8%) participants, including 7/19 (36.8%) among anti-HBs responders compared with 1/12 (8.3%) among non-responders. Although all participants achieving functional cure had a baseline HBsAg levels below 1,000 IU/mL in the ENSURE study, 4/7 (57.1%) of anti-HBs responders achieving functional cure had baseline HBsAg levels between 1,154 and 3,086 IU/mL at enrollment in the prior BRII-179-835-001 study. After NA discontinuation, no new treatment-related adverse events (TRAE) were reported. Most TRAEs resolved during the post EOT follow-up period. Participants achieving sustained HBsAg loss through combination therapy demonstrated favorable off-NA outcomes, characterized by infrequent HBV DNA rebound and no ALT elevations. In a separate oral presentation, Dr. Nina Le Bert will report findings from a translational study evaluating immunological responses associated with BRII‑179 using samples from the ENSURE and prior BRII-179-835-001 trials. The study identified a novel mechanism whereby BRII‑179 induced CD4+ T‑cell response targeting epitope sequences in the Pre-S1 region that are mismatched to circulating HBV genotypes. These vaccine‑induced T cells remained functionally stable for over two years, persisted during subsequent PEG-IFNα and siRNA treatment. Notably, these T‑cell responses were associated with progressive maturation of HBs‑specific B cells during treatment, an effect linked to enhanced HBsAg loss rates. These findings provide new insights into the potential mechanisms underlying BRII‑179–mediated functional cure. For more information about Brii Bio's HBV programs visit . About Hepatitis B Hepatitis B virus (HBV) infection is one of the world's most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2] About BRII-179 BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the "CDE") of China's National Medical Products Administration (the "NMPA") granted BRII-179 Breakthrough Therapy Designation. About Elebsiran Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade HBV RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020. In May 2024, the CDE of China's NMPA granted elebsiran Breakthrough Therapy Designation. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to improve patients' health by addressing high unmet medical needs with limited treatment options. The Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in both China and the United States. For more information, visit . SOURCE Brii Biosciences Limited 21% more press release views with Request a Demo

Clinical ResultPhase 2Breakthrough TherapyVaccine

18 May 2026

·www.biospace.com

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in “Best of EASL 2026” by EASL - Poster presentation of Week 48 subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for poster tour by EASL SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phase 2 SOLSTICE trial Format: Oral presentation Session: General Session II Presenter: Tarik Asselah Date: May 29, 2026 Time: 12:15 p.m. to 12:30 p.m. CEST SOLSTICE Week 48 subgroup analysis: Impact of BMI on ALT normalization after successful viral control in participants with chronic hepatitis delta virus infection treated with tobevibart plus elebsiran Format: Poster presentation Session: Poster Tour - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Presenter: Alina Jucov Date: May 29, 2026 Time: 4:15 p.m. to 5:00 p.m. CEST This poster will also be available as part of the following session: Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Date: May 27, 2026 Time: 8:30 a.m. to 5:00 p.m. CEST About Chronic Hepatitis Delta (CHD) CHD is the most severe form of chronic viral hepatitis 1 and was recently classified as carcinogenic by the International Agency for Research on Cancer. 2 People living with the disease rapidly progress to cirrhosis, liver failure 3 and liver-related death. 1 Because ongoing hepatitis delta virus (HDV) replication drives disease progression, achieving undetectable virus, as defined by HDV RNA TND (target not detected), is considered an important virologic marker associated with improved clinical outcomes in CHD. 4 Individuals with CHD who have detectable HDV RNA are at a higher risk of experiencing any liver-related event, including developing compensated and decompensated cirrhosis, hepatocellular carcinoma, liver transplantation and mortality, compared to patients with undetectable HDV RNA. 4 There are currently no approved treatments in the U.S., and options are limited in the European Union and globally. About Tobevibart and Elebsiran Tobevibart and elebsiran are investigational agents being evaluated as a novel combination regimen administered monthly as two separate sequential subcutaneous injections for the treatment of CHD. The combination is designed to disrupt the HDV life cycle at multiple points by addressing both viral entry and the sustained presence of hepatitis B surface antigen (HBsAg) that enables ongoing HDV replication. Tobevibart is an investigational broadly neutralizing monoclonal antibody (mAb) targeting HBsAg. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology’s proprietary mAb discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor’s Xtend™ technology to extend half-life. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of HBsAg. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. References: 1 National Institute of Diabetes and Digestive and Kidney Diseases. Hepatitis D. NIDDK. Published November 2024. Accessed September 2025. Hepatitis D - NIDDK (nih.gov) . 2 Karagas, Margaret R et al., “Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus” The Lancet Oncology , vol. 26, no. 8 (2025): 994 – 995. doi: 10.1016/S1470-2045(25)00403-6. 3 Center for Disease Control and Prevention. Hepatitis D FAQs. CDC. Published March 2020. Accessed September 2025. What is Hepatitis D - FAQ | CDC . 4 Gish R. (2024). Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis. Hepatology. 79:1129-1140. Contacts Media Contact Caren Scannell Director, Communications cscannell@vir.bio Investor Contact Kiki Patel, PharmD Head of Investor Relations kpatel@vir.bio

Phase 2Clinical Result

100 Deals associated with Elebsiran

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis D, Chronic	Phase 3	United States	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	Canada	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	Germany	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	Moldova	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	New Zealand	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	Pakistan	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	Romania	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	Ukraine	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis D, Chronic	Phase 3	United Kingdom	Vir Biotechnology, Inc.	12 Mar 2025
Hepatitis B, Chronic	Phase 2	Australia	Alnylam Pharmaceuticals, Inc.	03 Jul 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04749368 (CTgov)	Phase 2	Hepatitis B, Chronic	91	BRII-835 (VIR-2218) (Cohort A)	cohsiontjz = pwlqfvrzau uizsbimebh (rxoabtplju, rainzlidwb - qlzlhsqrqz) View more	-	23 Jul 2026
				IFN-α+BRII-179+BRII-835 (VIR-2218) (Cohort B)	cohsiontjz = hvswupxbdh uizsbimebh (rxoabtplju, mqcwceapao - kkfcdtsyfy) View more
NCT04412863 (CTgov)	Phase 2	Hepatitis B, Chronic	84	VIR-2218 (Cohort 1d: VIR-2218 200 mg Q4W x 6 on NRTI)	oqmfnvvoph = qqvibasvfz jdcqnjamwr (vmwjxguqyf, mdjxqoqwwz - nhmlmqwmou) View more	-	16 Apr 2026
				PEG-IFNα+VIR-2218 (Cohort 2d: VIR-2218 200 mg Q4W x 6 + PEG-IFNα 180 µg QW x 12 Starting at Week 12 on NRTI)	oqmfnvvoph = mxgstmbofr jdcqnjamwr (vmwjxguqyf, kgxudjxhkj - bdcezbdcef) View more
NCT05612581 (CTgov)	Phase 1/2	Hepatitis B, Chronic	33	TDF+VIR-3434 (STRIVE: Cohort 1a (VIR-3434 + TDF))	vjlllmlyfv(rcaacbegmg) = uuzshszqwe mhcyvsjfbj (tmkdoihwel, jnjkgublku - oqzwtptpbp) View more	-	26 Nov 2025
				TDF+VIR-3434 (STRIVE: Cohort 2a (VIR-3434 + TDF))	vjlllmlyfv(rcaacbegmg) = tmxdecgtrq mhcyvsjfbj (tmkdoihwel, vhdjwxumwp - fkxuwlfibm) View more
NCT05461170 (Pubmed \| N Engl J Med)	Phase 2	Hepatitis D	65	Tobevibart plus Elebsiran	veyqsbtjyn(jnxlrykmds) = swjzqqdvod gilyvazdzq (vinvmtzcfd ) View more	Positive	09 Nov 2025
				Tobevibart	veyqsbtjyn(jnxlrykmds) = dpvhgylfil gilyvazdzq (vinvmtzcfd ) View more
ENSURE (PRNewswire) Manual	Phase 2	Hepatitis B	28	BRII-179 (Cohort 4 + previously responded to BRII-179)	ahuuyabeuh(spkymeitqa) = umedsophux iolqnnqjci (stuuhtiwgn )	Positive	21 Aug 2025
				BRII-179BRII-179 (Cohort 4 + previously non-responders to BRII-179)	ahuuyabeuh(spkymeitqa) = rsobllbetx iolqnnqjci (stuuhtiwgn )
NCT04856085 (MARCH, Company_Website) Manual	Phase 2	Hepatitis B, Chronic	83	Tobevibart + Elebsiran	pshvxnjkyl(adqbgzbwdd) = uhytlxqziv inigcezhma (iymswfwyae ) View more	Positive	09 May 2025
				Tobevibart + Elebsiran + PEG-IFNα	pshvxnjkyl(adqbgzbwdd) = ahcniobflz inigcezhma (iymswfwyae ) View more
NCT05970289 (ENSURE, PipelineReview) Manual	Phase 2	Hepatitis B, Chronic	31	Elebsiran + PEG-IFNα (Cohort 4)	ampeaiczoi(zegcuyjlww) = ayvaoyyckm eqjcquvfeg (tdqbllicmh )	Positive	31 Mar 2025
				Elebsiran + PEG-IFNα (Cohort 4 + BRII-179 responders)	ampeaiczoi(zegcuyjlww) = ntvrdyoikj eqjcquvfeg (tdqbllicmh )
NCT03672188 (Pubmed \| Lancet Gastroenterol Hepatol)	Phase 1/2	Hepatitis B, Chronic	-	VIR-2218 200 mg + Pegylated interferon-alfa-2a	caoggpyfbl(lijyijyhdm) = 20% in cohort 1, 27% in cohort 2, 44% in cohort 3, 39% in cohort 4, 46% in cohort 5, 40% in cohort 6 nliycaymbb (zjbyihizkq ) View more	-	01 Dec 2024
NCT05970289 (ENSURE, NEWS) Manual	Phase 2	Hepatitis B	-	Elebsiran 200 mg+PEG-IFNα	lubcfxczjn(zjegpyjzsg) = avpgjdzbjz yntkkoarls (dhasgiajvz ) View more	Positive	19 Nov 2024
				Elebsiran 100mg+PEG-IFNα	lubcfxczjn(zjegpyjzsg) = xzvaopmfhk yntkkoarls (dhasgiajvz ) View more
NCT04507269 (CTgov)	Phase 2	Hepatitis B, Chronic	21	VIR-2218 (Part 1: VIR-2218 50 mg)	xxvdliuphh = czxnotmewl ruxfpttsrs (vmkneeqzmy, zqqgenjmgc - skhlyjqkvl) View more	-	26 Aug 2024
				VIR-2218 (Part 1: VIR-2218 100 mg)	xxvdliuphh = zyxctgdxid ruxfpttsrs (vmkneeqzmy, vpgqhkuzlk - gnepvzango) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis